- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Glenmark Pharmaceuticals Inc., USA has launched Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), a product bioequivalent and therapeutically equivalent to Xalatan® Ophthalmic Solution, 0.005% from Upjohn US. The annual sales for Xalatan® reached approximately $113.5 million, highlighting a significant market opportunity. This marks Glenmark's fourth ophthalmic product, further expanding its portfolio in the ophthalmic channel, showcasing a strategic alignment with market needs.
Marc Kikuchi, President & Business Head, North America, expressed enthusiasm about this addition, reinforcing the company’s commitment to providing quality solutions. With its advanced manufacturing capabilities across 11 facilities and operations in over 80 countries, Glenmark continues to position itself as a leader in the pharmaceutical sector. This development presents a positive outlook for investors, with potential growth in the ophthalmic market.